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Abstract
Background: Epidermal growth factor receptor (EGFR) mutations enable constitutive active downstream signaling
of PI3K/AKT, KRAS/ERK and JAK/STAT pathways, and promote tumor progression by inducing uncontrolled proliferation,
evasion of apoptosis and migration of non-small cell lung cancer (NSCLC). In addition, such EGFR mutations increase the
susceptibility of patients with NSCLC to tyrosine kinase inhibitor (TKI) therapy, but treated patients will invariably relapse
with resistant disease. A global understanding of underlying molecular mechanisms of EGFR signaling may improve the
management of NSCLC patients.
Methods: microarray analysis was performed to identify PI3K/AKT-regulated miRNAs. Phosphoproteomic analysis
and cell based assays were performed using NSCLC cell lines lentivirally transduced with anti-miR or miR
overexpressing constructs.
Results: Here, we show that 17 miRNAs including members of the miR-17~ 92 cluster are dysregulated following
PI3K/AKT inhibition of EGFR mutant NSCLC cells. Bioinformatics analysis revealed that dysregulated miRNAs act in
a concerted manner to enhance the activity of the EGFR signaling pathway. These findings were closely mirrored
by attenuation of miR-17~ 92 family member miR-19b in NSCLC cell lines which resulted in reduced phosphorylation of
ERK, AKT and STAT and effector proteins in EGFR mutant NSCLC cells. Consistent with this finding, cell cycle progression,
clonogenic growth and migration were reduced and apoptosis was enhanced. Co-treatment of NSCLC cells with the
tyrosine kinase inhibitor (TKI) gefitinib and anti-miR-19b construct reduced migration and clonogenic growth in
a synergistic manner suggesting that EGFR and miR-19b act together to control oncogenic processes. Serine/
threonine phosphatase PP2A subunit PPP2R5E and BCL2L11 encoding BIM were identified as major targets of
miR-19b by target validation assays. Consistent with this finding, PP2A activity was strongly enhanced in NSCLC
transduced with anti-miR-19b construct, but not in cells co-transduced with anti-miR-19b and shPPP2R5E, suggesting
that PPP2R5E is a major constituent of the PP2A complex. Accordingly, enhanced proliferation by miR-19b was due to
targeting PPP2R5E. In contrast, apoptosis resistance was mainly due to targeting BCL2L11.
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Conclusion: Our results provide insight into the importance of targeting PPP2R5E and BCL2L11 by miR-19b in oncogenic
processes of NSCLC. Attenuation of miR-19b expression could potentially be exploited in adjuvant therapy of EGFR
mutant NSCLC.
Keywords: Apoptosis, Proliferation, Epidermal growth factor receptor, microRNA, Non-small cell lung cancer,
Serine-threonine phosphatase
Background
Lung cancer is the leading cause of cancer-related death
worldwide with a mean 5-year survival rate of less than
15% [1]. Platinum-based therapy is the standard of care
for patients with metastatic non-small cell lung cancer
(NSCLC), the most common subtype of lung cancer [2].
The introduction of targeted therapy using tyrosine kin-
ase inhibitors (TKI) increased overall survival of patients
with metastatic NSCLC harboring activating mutations
in the epidermal growth factor receptor (EGFR) com-
pared with standard cytotoxic therapy [3]. Nevertheless,
25% of these patients respond poorly to the therapy and
virtually all patients eventually relapse owing to acquisi-
tion of secondary EGFR mutations or reactivation of sig-
naling pathways downstream of EGFR [4, 5]. Thus,
despite promising initial clinical responses in some pa-
tients, the 5-year survival rate of patients treated with
TKI remains relatively low [6]. A deeper understanding
of underlying molecular processes of EGFR signaling
may provide insights into improving the management of
EGFR-mutant lung cancer patients.
The EGFR signaling pathway is among the most
important drivers of lung tumorigenesis: mutations in
EGFR (10–15%) or mutations or translocations of down-
stream effectors including KRAS (25–40%) and ALK
(5–7%) are frequently found in Caucasian NSCLC pa-
tients [7]. This results in overactivation of effector path-
ways including the RAS/ERK, JAK/STAT AKT/mTOR
pathway, and enhancement of five of six hallmarks of
cancer including evasion of apoptosis, sustained angio-
genesis, resistance to antigrowth signals, invasion and
metastasis and self-sufficiency in growth signals [4].
The activity of kinases in the EGFR signaling pathway
is controlled by phosphatases, which remove the phos-
phate groups within minutes after phosphorylation [8].
Thus, kinases and phosphatases are equally important in
modulating the activity of signaling pathways, but the
role of phosphatases is far less understood. Serine/threo-
nine phosphatase PP2A is a heterotrimeric protein com-
posed of a structural subunit A, a catalytic subunit C
and a regulatory subunit B. Members of the regulatory B
subunit exhibit tissue-specific expression profiles, and
are implicated in diverse cellular functions by recruiting
PP2A to specific substrates [9]. PP2A is a critical regula-
tor of ERK and AKT, and controls downstream effectors
of EGFR including NF-κB, TP53 and Bcl2 [9–11]. The
importance of PP2A in EGFR signaling is also illustrated
by the finding that administering SMAPs, small
molecule activators of PP2A, results in substantial inhib-
ition of KRAS-driven tumor growth [12]. Conversely,
procadherin 7, an endogenous inhibitor of PP2A, which
acts through SET, potentiates ERK signaling through
EGFR and KRAS, and promotes transformation of KRAS
transduced bronchial epithelial cells [13]. Consistent
with these findings, PP2A is repressed in NSCLC by
inactivating mutations, overexpression of PP2A inhibi-
tory proteins or post-translational modifications [14],
but in most cases the underlying molecular mechanisms
are unknown.
MicroRNAs (miRNAs), short regulatory RNA se-
quences, which control gene expression at the post-
transcriptional level, are critical regulators of signaling
pathways. They act as signal amplifiers or attenuators
and promote the cross-talk between signaling pathways
[15]. In a previous study, we showed that miR-29b is a
mediator of NF-κB signaling in KRAS-transduced
NSCLC [16]. In this study, we define miR-19b as a medi-
ator of the PI3K/AKT signaling pathway. miR-19b is the
major oncogenic miRNA of the miR-17-92 cluster, and
plays a central role in tumorigenesis of B-cell lymph-
omas [17–19]. miR-19b is also an oncogenic miRNA in
NSCLC, and is implicated in proliferation [20], attenu-
ation of apoptosis and migration [21]. Upregulation of
miR-19b and its paralogue miR-19a in the tumor tissue
as well as in the serum is associated with poor prognosis
of patients with NSCLC [22–24]. Here we report that
miR-19b potentiates EGFR signaling by targeting PP2A
B subunit PPP2R5E and confers apoptosis resistance by
targeting BCL2L11 encoding the BH3 domain-
containing protein BIM. Our results provide insight into
oncogenic processes of miR-19b in NSCLC cells.
Methods
Cell lines and drug treatment
EGFR mutant NSCLC cell lines PC9 and PC9ER (kindly
provided by PD Dr. A. Arcaro, Department of Clinical
Research, University of Bern, Bern, Switzerland),
HCC4011 (kindly provided by Prof. M.D. A. F. Gazdar
and Prof. M.D. J. Minna, University of Texas Southwest-
ern Medical Center, Dallas, TX, USA) and HCC827
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(American Type Culture Collection, Manassas, VA,
USA) were used in this study. All cell lines were cultured
in complete Roswell Park Memorial Institute medium
(cRPMI) (Sigma-Aldrich, Buchs, Switzerland), supple-
mented with 4 mmol/l L-alanyl-L-glutamine (Bioswisstec
AG, Schaffhausen, Switzerland) 1% penicillin/strepto-
mycin and 10% fetal bovine serum (Sigma-Aldrich) at
37 °C and 5–10% CO2. Cell lines were authenticated by
STR profiling (Microsynth, Balgach, Switzerland) in
March 2016.
EGFR inhibitors Gefitinib (Selleckchem, Munich,
Germany) and Afatinib (Selleckchem), PI3K-inhibitor
LY294002 (Selleckchem), and MEK-inhibitor U0126 (Sell-
eckchem) were used at concentrations indicated in the text.
Constructs
Luciferase reporter constructs were obtained by cloning
double-stranded oligonucleotides encompassing the wild
type or mutated miR-19b target sites from PPP2R5E or
BCL2L11, respectively, into the XbaI and XhoI sites of
pmiRGLO Dual-Luciferase miRNA target expression
vector (Promega, Dübendorf, Switzerland). Lentiviral ex-
pression vector hsa-miR-19b-NW was obtained by cloning
a PCR product encompassing the pri-miRNA sequence of
miR-19b into the NotI and EcoRI sites of PMIRH125b-
1PA-1. Oligonucleotides used for cloning are indicated in
Additional file 1: Table S1. Antisense hsa-miR-19b and
antisense scrambled control (System Biosciences, San
Francisco, CA) were used for attenuation of miR-19b-3p
levels. Gene knockdown experiments were performed
using shPPP2R5E, shBCL2L11 and shc002 constructs
(Sigma-Alderich, Buchs, Switzerland).
Transfections and luciferase assays
NSCLC cells were transfected with 100 ng pmiRGLO vec-
tor using transfection reagent HiPerFect (Qiagen,
Hombrechtikon, Switzerland) according to the fast-
forward protocol provided by the supplier. Luciferase re-
porter assays were performed 48 h post transfection [25].
Lentiviral transduction and cell-based assays
Lentiviral production was carried out as described [26].
Transduction efficiency was assessed for GFP expression
3 days post transduction by FACS. Transduced cells
were sorted by FACS or selected with 0.5 μg/mL puro-
mycin (Sigma-Aldrich).
Apoptosis was induced by treating cells with 10 ng/
ml TNFα (PeproTech, Rocky Hill, NJ, USA) in
combination with 0.5 μg/mL actinomycin D (Sigma-
Aldrich) for 6 h. Apoptosis and viability were assessed
using the ApoTox-Glo Triplex assay (Promega) as de-
scribed [25]. Alternatively, apoptosis was assessed
using the pacific blue annexin V apopotosis detection
kit with PI (LucernaChem). Annexin V/propidim
iodide-positive cells were analyzed using a LSR II
Flow Cytometer (Becton Dickinson) and FlowJo soft-
ware version9.8.2 (Tree Star).
Anchorage-dependent clonogenic assay was per-
formed in six-well plates seeded with transduced cells
and cultured for 10 days in cRPMI. Colonies were fixed
with methanol and stained with 0.5% crystal violet solu-
tion (Sigma-Aldrich) for 30 min, washed with deionized
water and lysed in 1 mL 1% (W/V) SDS. Clonogenic
growth was assessed by measuring the absorption of
the lysate at 505 nm using an Infinite 200 PRO plate
reader (TECAN, Männedorf, Switzerland). At least
three independent experiments were carried out for
each experiment.
Cell proliferation was assessed by 5-bromo-2-deoxyuri-
dine (BrdU) incorporation assay according to the manu-
facturer’s instructions (Roche Diagnostics). Four thousand
cells were plated per well of a 96-well plate. BrdU incorp-
oration was performed one day post-seeding for 5 h. At
least three independent experiments were carried out for
each experiment.
Wound healing assay was performed as described [27].
Sixty thousand cells were allowed to adhere for 4–6 h in
a 100 μL drop of cRPMI placed in the middle of a 6-well
culture dish. The monolayer was artificially injured by
scratching across the plate with a 200 μL pipette tip.
Wells were washed twice with cRPMI to remove de-
tached cells and wound healing was monitored over a
period of 24 h using the imaging system Cell-IQ
(Canibra, Bramsche, Germany) and the CellActivision
software version R1.03.01 (Yokogawa Electric Corpor-
ation, Republic of Korea).
Phosphatase activity assay
Cell extracts were prepared as described [28]. Following
centrifugation for 10 min at 12000 g, the soluble fraction
was passed through a NucAwayTM Spin column (Fisher
Scientific, Reinach, Switzerland) equilibrated with stor-
age buffer and the protein concentration in the eluate
was determined using the Qubit protein assay (Thermo-
Fisher). 15 ng of the eluate was analyzed using the Ser/
Thr phosphatase assay (Promega) according to manufac-
turer’s instructions. Cell lysates were pre-incubated at
37 °C for 10 min and the reaction was continued in the
presence of PP2A substrate for 2 h. Phosphatase activity
was also assessed in the presence of 25 μM PP2A inhibi-
tor LB-100 (Selleckchem). The reaction was stopped by
the addition of molybdate dye and released Pi was quan-
tified by absorption spectroscopy at 600 nm. Phosphat-
ase activity in the presence of Pi depleted H2O was used
as a blank. The assay was linear for the indicated incuba-
tion period and the amount of protein extract.
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Phospho-kinase array and western blot analysis
Phospho-kinase array analysis was performed using
800 μg total protein according to manufacturer’s instruc-
tions (R&D Systems, Zug, Switzerland). Briefly, cell lysates
were mixed with biotinylated detection antibodies and
phospho-proteins were captured using antibodies spotted
in duplicate on nitrocellulose membranes and quantified
by chemoluminescence. Following background subtrac-
tion, the average signal intensity of pair of duplicate spots
was normalized to the overall signal intensity.
For Western blot analysis 20 μg total protein was
loaded per lane on a 4–20% Mini-PROTEAN TGX Gel
(Bio-Rad Laboratories AG, Reinach, Switzerland).
Separated proteins were transferred to PVDF mem-
branes using the transfer turbo system (Bio-Rad). Mono-
clonal antibodies used in this study were directed
against AKT (40D4, 1:1000, Cell Signaling Technolo-
gies), phospho-AKT (D7F10, Ser473, 1:1000, CST),
CCND1 (SP4, 1:100, Cell Marque), ERK1/2 (L34F12,
1:2000, CST), phospho-ERK1/2 (D13.14.4E, Thr202/
Tyr204, 1:2000, CST), GSK3β (3D10, 1:1000, CST),
phospho-GSK3β (D85E12, Ser9, 1:1000, CST), PPP2R5E
(5A5-1F3, 1:1000, Millipore), BIM (C34C5, 1:1000,
CST), PTEN (138G6, 1:1000, CST), S6 Ribosomal pro-
tein (54D2, 1:1000, CST), phospho-S6 Ribosomal protein
(D57.2.2E, Ser235/236, 1:1000, CST), STAT3 (124H6,
1:1000, CST), phospho-STAT3 (D3A7, Tyr705, 1:1000,
CST), α-tubulin (clone DM1A, 1:1000, CST), GAPDH
(clone D16H11, 1:1000, CST). Secondary polyclonal-
donkey anti-rabbit-HRP and donkey anti-mouse-HRP
(Jackson Immuno Research, Suffolk, UK) were used at
1:5000. Protein levels were normalized to α-tubulin.
Visualization and quantification of protein bands were
performed using a luminescent image analyzer
LAS-4000 (Fujifilm, Dielsdorf, Switzerland) and Multi
Gauge software (Fujifilm v.3.0).
RNA isolation and real-time PCR
RNA extraction and real-time PCR were performed as
described [29]. miRNA levels were analyzed using
TaqMan Assay (Applied Biosystems), and mRNA levels
were analyzed using QuantiTec Primers (Qiagen).
miRNA and mRNA levels were normalized to the levels
obtained for RNU48 and GAPDH, respectively. Changes
in expression were calculated using the ΔΔCT method.
High-throughput miRNA NanoString profiling
One hundred and fifty ng total RNA was analyzed using
the nCounter Human miRNA Expression Assay Kit
H_miRNA_V3 (NanoString, Seattle, WA, USA) accord-
ing to manufacturer’s instruction. Each sample was
scanned for 555 fields of view (FOV) using the nCounter
Digital Analyzer. nCounter data imaging QC metrics re-
vealed no significant discrepancy between the FOVs
attempted, and the FOVs counted. The binding density
for the samples ranged between 0.08 and 0.21 within the
recommended range.
Statistical and bioinformatics analysis
NanoString normalization
Positive control correction was used to confirm ligation
of the miRNAs to the tags. The positive correction was
performed by
c m
s
 
In this equation c is count for a microRNA in a given
sample, m is the mean of the sum of the positive controls
across all samples, and s is the sum of all of the positive
controls for that given sample. We modified NanoStriDE
web application and implemented DESeq ANODEV (uses
DESeq’s built in normalization methods) in an R script.
Negative control (unique probes for which no target
sequence is present in the human transcriptome) subtrac-
tion and normalization of positive control corrected data
were performed using “NanoStringNorm” and “NanoS-
tringDiff” R packages (available in CRAN). We used the
mean of the negative controls summed with 2 standard
deviations of the negative controls. mRNA sequences
(ACTB, B2M, GAPDH, RPL19 and RPLP0) were used to
confirm successful hybridization and to normalize varia-
tions in sample input.
Differential expression profiling of normalized microRNAs
The normalized count data were modelled over-dispersed
Poisson data using a negative binomial model in the
EdgeR Bioconductor package.
Hierarchical clustering and heatmap
Hierarchical clustering and the associated heatmap for
miRNA profiling data was generated with the function
heatmap2 in the R package gplots or GENE-E R package
[30]. We used pairwise correlation matrix between items
based on Pearson correlation method. The correlation
matrix was converted as a distance matrix. Finally, clus-
tering was calculated on the resulting distance matrix.
We used average linkage method to calculate the dis-
tance matrix.
Volcano graph
miRNA content in DMSO treated cells were compared
to PI3K inhibitor treated cells.
-log10 adjusted p value was plot against log2 fold
change of corresponding samples using a custom R
function.
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Prediction of altered canonical pathways based on
differentially expressed microRNAs
The prediction of targets of differentially regulated micro-
RNAs was done by TargetScan and the experimentally ob-
served relationships was collected from TarBase. The
significance values for the canonical pathways was calcu-
lated by Fisher’s exact test right-tailed. The significance in-
dicates the probability of association of microRNA targets
from our dataset with the canonical pathway by random
chance alone. For Nanostring dataset, the intensity of al-
teration of mRNAs of each canonical pathway was calcu-
lated based on reverse regulation of microRNA fold
changes. An ‘enrichment’ score [Fisher’s exact test (FET)
P-value] that measures overlap of observed and predicted
regulated gene sets was calululated.
Pathway analysis based on the dataset from the
phosphatase array
In order to identify upstream regulators and causal net-
work master regulators that can potentially create the
changes in phosphorylation levels of the proteins in our
phosphoproteomics dataset, Phosphorylation Core
Analysis tool in IPA was used to predict the affected ca-
nonical pathways [30].
Word cloud
To visualize gene enrichment data from a pathway ana-
lysis dataset, a cloud was created using Wordle.net and
Word cloud R package. The font size of a gene (tag) is de-
termined by its incidence in the pathway analysis data set.
Prediction of biological function of canonical pathways
We used “BioFun” R Package (available upon request) tool
that examines involvement of each IPA canonical pathway
in the Biological Function Classification Database of IPA
known as “Ingenuity canonical pathway” and counts the
number of pathways involved in a specific biological func-
tion. The results are illustrated as radar graphs.
Statistical differences
Statistical differences were calculated using the unpaired
two-tailed Student’s t-test in GraphPad Prism software
(v.7.0a). Statistical significance was achieved at a probability
of *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns,
not significant.
Results
Expression profiling of PI3K/AKT effector miRNAs
To identify effector miRNAs of the PI3K/AKT pathway,
the NSCLC cell line PC9 containing a constitutive active
EGFR mutation was treated with the PI3K inhibitor
LY294002 and changes in global miRNA expression was
assessed using the NanoString technology. Thirty-three
miRNAs were upregulated and 71 miRNAs were
downregulated by LY294002. Hierarchical clustering and
heatmap analysis revealed clear distinction of both ex-
perimental groups (Fig. 1a). A volcano plot was con-
structed to display fold change and p-value, which
allowed the identification of 16 miRNAs that were
downregulated and 1 miRNA that was upregulated using
a cutoff ±0.4 log2 FC (Fig. 1b, and Table 1). miR-100-5p,
miR-125-5p, miR-205-5p, miR-19b-3p, miR-7b-5p, miR-
9-5p, miR-20a/b-5p and miR-374a-5p, which were
downregulated in previous studies using EGFR knock-
down cell lines [31–33], were also significantly downreg-
ulated by LY294002, but their role in PI3K/AKT
signalling has not yet been addressed.
Interestingly, IPA revealed that there is a significant
bias for LY294002-regulated miRNAs towards the EGFR
signaling pathway (Additional file 2: Figure S1a). The
pathways were built in silico using highly predicated and
experimentally validated targets of 17 top regulated and
significant miRNAs shown in Table 1. Notably, targets of
these miRNAs might be involved in glioblastoma signal-
ing (PI3K signaling pathway), STAT3 Pathway, TGF-β,
ERK5, Rho Family GTPases, PTEN, ERK/MAPK, and
EGF pathways. MAPK1, PIK3 subunits PIK3R3, PIK3R1,
PIK3CA and PK3CB, ATM, KRAS, NRAS and FGR were
involved in 70% of the regulated pathways (Additional
file 2: Figure S1b). Pathway analysis information was fur-
ther interrogated using the IPA Biological Function Clas-
sification Database, which allows for the identification of
biological functions affected by specific miRNAs [30].
Cellular immune response, cellular growth, proliferation
and development are most likely processes affected by
LY294002-regulated miRNAs (Additional file 2: Figure
S1c). Thus, we concluded that miRNAs that are effectors
of the EGFR signaling pathway are also implicated in
modulating cellular processes elicited by EGFR signaling.
Among the miRNAs that are dysregulated by
LY294002, family members of the miR-17~ 92 cluster,
including miR-19a, miR-18a, miR-19b, miR20a and miR-
20b, seemed to be most prominent. Collective read
number of the members of this miRNA cluster was
5282, making it the most abundant cluster among
LY294002-regulated miRNA species (top 5% expressed
miRNA). IPA conducted using the predicted targets of
family members of the miR-17~ 92 cluster closely mir-
rored the findings obtained with LY294002-regulated
miRNAs (data not shown). This is in line with previous
observations that members of this miRNA cluster are
among the most potent oncogenic miRNAs [18, 19].
We focused on miR-19b in subsequent experiments
for the following reason: miR-19b is (i) the most import-
ant oncogenic miRNA of the miR-17~ 92 cluster
[17–19], is (ii) associated with NSCLC aggressiveness
[34], and is (iii) upregulated during transformation and
progression of NSCLC [20]. miR-19b and its paralog
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miR-19a are strongly regulated by LY294002 (Table 1).
Pharmacologic inhibitors of EGFR (gefitinib and afatinib)
resulted in 1.4–2.5-times lower miR-19b levels in 3 inde-
pendent NSCLC cell lines harboring constitutive active
EGFR mutations (Fig. 1c), but miR-19b levels were not
affected by gefitinib in gefitinib-resistant PC9-ER cells,
confirming the specificity of the TKI. Likewise, the PI3K
inhibitor LY294002 resulted in 1.3–1.7-times lower miR-
19b levels consistent with the results from the Nano-
string analysis. In contrast, the MEK inhibitor U0126
had no effect on the miR-19b expression level (Fig. 1c),
while it significantly reduced the level of KRAS-induced
miR-29b [16] under the same conditions (data not
shown). None of the TKIs resulted in apparent cell death
under these conditions (Additional file 3: Figure S2). In
conclusion, miR-19b is regulated by the PI3/AKT branch
of the EGFR signaling pathway. The promoter region of
the miR-17~ 92 cluster contains binding sites for
multiple transcription factors including myc, E2F, SP1
and NFY [35], but it remains to be shown if PI3/AKT
affects miR-17~ 92 expression through either of these
transcription factors.
miR-19b affects phosphorylation of kinases of the EGFR
signaling pathway
To assess whether miR-19b modulates the activity of the
EGFR signaling pathway, phosphoproteomic analysis
was performed using a phosphokinase antibody array
(R&D Systems). To this end, PC9 cells were transduced
with a lentivirus expressing the anti-miR-19b construct,
which significantly lowered the miR-19b levels compared
to the control (Additional file 4: Figure S3). Serine/
threonine phosphoproteins including kinases from the
major branches of the EGFR pathway such as ERK1/2,
p38a, JNK1/2/3, AKT1/2/3 and STAT3 as well as down-
stream effectors such as p53, mTOR, S6 kinase, GSK-3a/
b, c-Jun and Chk-2 were strongly reduced in the miR-
19b knockdown cells (Fig. 2a). Tyrosine kinases such as
EGFR were also affected.
Western blot analysis confirmed our findings of the
phosphokinase antibody array (Fig. 2b). Overexpression
of miR-19b resulted in enhanced phospho-ERK1/2,
phospho-AKT and phospho-STAT protein levels.
Consistent with these findings, phosphorylation of effec-
tors of the AKT pathway such as pS6 and pGSK3β were
a b
c
Fig. 1 miR-19b is regulated by the PI3K/AKT branch of the EGFR signaling pathway. a Heat map clustering of miRNAs that are dysregulated by the PI3K
inhibitor LY294002. PC9 cells were treated with 20 μM LY294002 or DMSO control for 72 h and expression of 800 miRNAs was analyzed by NanoString
using the nCounter Human miRNA Expression Assay Kit (n = 3). b Volcano plot of dysregulated miRNAs described in (A) using a cutoff ±0.4 log2 fold
change (FC) (n = 3). c miR-19b expression level by real-time qPCR relative to RNU48 in EGFR mutant NSCLC cells treated with 1.25 μM gefitinib, 1.25 uM
afatinib, 20 μM LY294002 and 10 μM U0126 for 72 h. Results are presented as mean ± SD (n = 3). ns, not significant. *, p < 0.05; **, p < 0.01; ***, p < 0.001
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significantly enhanced. Conversely, attenuation of miR-
19b expression resulted in reduced phosphorylation of
above mentioned proteins. Under the same experimental
condition, PTEN, a known target of miR-19b, was sig-
nificantly enhanced in miR-19b-attenuated cells, but
overexpression of miR-19b did not significantly affected
PTEN protein levels.
Activity profile of 45 phosphoproteins (shown in Fig. 2a)
was submitted for pathway analysis based on phosphoryl-
ation profile of IPA platform (Additional file 5: Figure
S4a). Upstream analysis of these pathways indicates EGF
as the main upstream element (Additional file 5: Figure
S4b). In conclusion, down-regulation of miR-19b inhibits
all major branches of the EGFR signaling pathway.
Interestingly, analysis of regulated pathways revealed an
almost complete overlap of biological functions deduced
from the phosphoprotein array in miR-19b-attenuated
cells and biological functions built on targets of
LY294002-regulated miRNAs (Additional file 2: Figure
S1c and Additional file 5: Figure S4c), indicating that
PIK3-regulated miRNAs share similar functions.
PP2A subunit PPP2R5E and BCL2L11 are major targets of
miR-19b
Gene network analysis based on the regulation profile of
the input elements from the phosphokinase antibody
array revealed that serine/threonine phosphatase PP2A,
tyrosine phosphatases PTPN and PTEN are likely to be
up-regulated in miR-19b-depleted cells (Additional file 5:
Figure S4d). These data are in agreement with the
observation that PTPN, PTEN and PP2A subunits are con-
firmed or predicted targets of miR-19b, respectively.
Targetscan (www.targetscan.org), miRDB (www.mirdb.org)
and DianaLab (http://diana.imis.athena-innovation.gr) da-
tabases revealed that PP2A regulatory B subunit PPP2R5E
harbors two sequence motifs in the 3′-untranslated region
that are complimentary to the miR-19b seed sequence
(Additional file 1: Table S1). To assess whether PPP2R5E is
a target of miR-19b, luciferase reporter assays were per-
formed. A luciferase reporter construct containing the up-
stream sequence motif from the PPP2R5E 3’UTR
(Additional file 1: Table S1) gave rise to enhanced lucifer-
ase activity in PC9 cells transduced with antisense-
miR19b-construct relative to the control. Conversely,
reduced luciferase activity was obtained in cells overex-
pressing miR-19b (Fig. 3a). In contrast, luciferase activity
was refractory to miR-19b expression using constructs, in
which the miR-19b binding site had been mutated (Fig. 3a
and Additional file 1: Table S1). These results confirm that
PPP2R5E is a direct target of miR-19b. Consistent with
these results, PPP2R5E mRNA levels were significantly
increased in three EGFR mutant NSCLC cell lines that
were stably transduced with antisense-miR19b-construct
(Fig. 3b). Under the same conditions, PPP2R5E protein
levels were increased in miR-19b attenuated cells. Con-
versely, PPP2R5E protein was slightly reduced in miR-
19b overexpressing PC9 cells, but not HCC4011 and
HCC827 cells (Fig. 3c). In addition, PP2A activity was
significantly reduced (62%) in miR-19b-overexpressing
cells, while attenuation of miR-19b resulted in en-
hanced PP2A activity (293%, Fig. 3d). Treatment of
cell lysates with LB-100, a specific inhibitor of PP2A,
completely abrogated PP2A activity, confirming the
specificity of the assay. In conclusion, PPP2R5E is a
relevant target of miR-19b.
The regulated pathway model described in Additional
file 5: Figure S4c suggests that miR-19b may also be im-
plicated in the regulation of apoptosis. Interestingly, tar-
get prediction databases revealed that Bcl2L11, which
encodes the apoptosis regulator BIM, is a potential tar-
get of miR-19b (Additional file 1: Table S1). Consistent
with this finding, attenuation of miR-19b enhanced lucif-
erase activity, while overexpression of miR-19b resulted
in reduced luciferase activity of pmirGLO constructs
harboring the predicted miR-19b binding site sequence
of Bcl2L11 (Fig. 3a), indicating that Bcl2L11 is a direct
target of miR-19b. Mutating the target site abrogated
regulation of luciferase activity by miR-19b. These re-
sults were confirmed by RT-qPCR (Fig. 3b) and Western
blot analysis (Fig. 3c) in three independent EGFR mutant
NSCLC cell lines.
Table 1 Top miRNAs regulated by the PI3K inhibitor LY294002
Rank miRNAs Fold
change
(log2)1
adjusted
p-value
1 hsa-miR-100-5p −2.30 2.15E-38
2 hsa-miR-125b-5p −2.23 3.40E-36
3 hsa-miR-205-5p −1.67 5.63E-21
4 hsa-miR-19a-3p2 −1.59 2.28E-14
5 hsa-miR-18a-5p2 −1.57 2.28E-14
6 hsa-miR-181a-5p 1.56 8.78E-13
7 hsa-miR-503-5p −1.44 7.17E-11
8 hsa-miR-19b-3p2 −1.43 1.50E-14
9 hsa-miR-196b-5p −1.25 6.66E-07
10 hsa-let-7b-5p −1.14 1.73E-09
11 hsa-miR-372-3p −1.12 1.25E-01
12 hsa-miR-9-5p −1.05 3.65E-08
13 hsa-miR-20a-5p + hsa-miR-20b-5p2 −1.04 3.65E-08
14 hsa-miR-422a −1.02 1.38E-05
15 hsa-miR-1180-3p −1.02 6.77E-07
16 hsa-miR-374a-5p −1.02 1.48E-07
17 hsa-miR-99b-5p −1.01 3.42E-06
1Fold change relative to DMSO treated cells. Cut off was set to ±0.4
log2FC (n = 3)
2OncomiR-1 cluster
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miR-19b controls EGFR-induced cellular processes
To assess the cellular processes regulated by miR-19b,
EGFR mutant NSCLC cell lines were transduced with
anti-miR-19b or miR-19b overexpression constructs. At-
tenuation of miR-19b levels resulted in enhanced spontan-
eous apoptosis relative to scrambled control (Fig. 4a, solid
white and grey columns and Additional file 6: Figure S5).
Tumor necrosis factor alpha (TNFα) in combination with
actinomycin D (ActD) elicited an up to 3.1-fold induction
of apoptosis in miR-19b-attenuated cells while control-
transduced cells were virtually unaffected indicating that
endogenous miR-19b levels are sufficient to protect cells
from induced apoptosis (Fig. 4a, hatched white and grey
columns and Additional file 6: Figure S5).
BrdU incorporation assay was performed to assess
proliferation. Pre-miR-19b-transduced cells showed in-
creased BrdU incorporation, while attenuation of miR-
19b expression resulted in reduced proliferation in
three independent NSCLC cell lines (Fig. 4b). Consist-
ent with this finding, anchorage-dependent clonogenic
growth was significantly increased in miR-19b overex-
pressing cells compared to scrambled control, whereas
miR-19b depletion significantly reduced colony forma-
tioncapacity (Fig. 4c).
The combinatorial effect of the inhibitors of miR-19b
and EGFR, which may either be synergistic, additive, epi-
static or suppressive, may provide a deeper insight into
the underlying molecular processes [36]. To this end, we
assessed clonogenic growth of miR-19b-attenuated cells
in the presence of the EGFR inhibitor gefitinib (Fig. 4d
and Additional file 7: Figure S6). The half maximal
inhibitory concentration (IC50) of gefitinib in control-
transduced and anti-miR19b–transduced PC9 cells were
5.4 nM and 2.0 nM, respectively. Thus, attenuation of
miR-19b results in a shift in gefitinib sensitivity by a
factor of 2.7. Likewise, attenuation of miR-19b in
HCC4011 cells gave rise to a shift in the IC50 of gefi-
tinib from 11.0 nM to 6.8 nM. Based on these synergistic
effects, we may conclude that EGFR and miR-19b act in
the same pathway.
a b
Fig. 2 Changes in phosphorylation elicited by miR-19b. a Phosphoprotein array of anti-miR19b–transduced PC9 cells relative to control (n = 4).
Signal intensity of pairs of duplicate spots is indicated. Only proteins that give rise to a signal intensity at least two fold above the background
and a fold change ≤ 0.8 relative to control are indicated. b Western blot analysis of pre-miR-19b and anti-miR-19b-transduced cells. Protein levels
were normalized to α-tubulin and presented relative to the control. Numbers below the immunoblots indicate relative expression values. Signal
ratio of phospho-specific antibody and pan-specific antibody for respective proteins are indicated in bold
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EGFR is also implicated in the regulation of cell migra-
tion. Wound closure over time was significantly reduced
in anti-miR19b–transduced cells compared to scrambled
control (Fig. 5a, b and Additional file 8: Video S1), which
is most clearly detected 16 h after wound formation. In
both cells lines, gefitinib treatment also resulted in re-
duced migration, but the combinatorial treatment with
anti-miR-19b and gefitinib resulted in a significantly
lower migration rate than gefitinib or anti-miR-19b
alone. In HCC4011 cells, the combined effect was clearly
synergistic (Fig. 5b) while it was additive in the case of
PC9 (Fig. 5a). Thus, EGFR and miR-19b act together to
control migration.
miR-19b induces proliferation and apoptosis resistance by
targeting PPP2R5E and BCL2L11
To assess if PPP2R5E and BCL2L11 are relevant targets
of miR-19b, we transduced PC9 cells with anti-miR19b
or anti-scrambled control, in combination with
shPPP2R5E, shBCL2L11 or shcontrol (shc002). In a first
experiment, PP2A activity was assessed (Fig. 6a). Attenu-
ation of miR-19b expression resulted in 2.5-fold higher
PP2A activity in cells co-transduced with anti-miR-19b
and shc002 (solid columns), but a significantly weaker
elevation of PP2A activity was observed in cells co-
transduced with anti-miR-19b and shPPP2R5E (hatched
columns). This indicates that miR-19b affects PP2A ac-
tivity by targeting PPP2R5E. PP2A catalytic subunit can
form complexes with multiple subunit B isoforms, each
of which contributes to PP2A activity. In miR-19b-
attenuated cells, PPP2R5E seems to be the major com-
ponent, since knocking down PPP2R5E resulted in 70%
less activity (Fig. 6a, compare solid grey and hatched
grey columns). In contrast, only ~30% PP2A complexes
seem to be associated with PPP2R5E in control-
transduced PC9 cells (compare solid white and hatched
white columns). As expected, PP2A activity was not al-
tered in the BCL2L11 knockdown (dotted columns). The
specificity of the assay was confirmed by treating cell
lysates with LB-100.
a
b
c
d
Fig. 3 PPP2R5E and BCL2L11 are direct targets of miR-19b. a Luciferase
reporter assay of PC9 cells transduced with pre-miR19b (pmiR19b),
pre-control (pmiRscr), anti-miR19b (αmiR19b) and anti-control (αscr) and
transfected with constructs containing the wild-type (TS) or mutated
(mTS) miR-19b target site from PPP2R5E or BCL2L11, respectively. Luciferase
activity is presented as mean ± SD relative to Renilla activity (n = 3).
b PPP2R5E and BCL2L11 mRNA levels by real-time qPCR in anti-miR19b–
transduced NSCLC cells. Results are presented as mean fold change
relative to the control ±SD, normalized to GAPDH (n = 3). c Western blot
analysis of pre-miR-19b and anti-miR19b–transduced NSCLC cells using
PPP2R5E and BCL2L11 specific antibodies. Protein levels were normalized
to α-tubulin and GAPDH and presented relative to the control. d PP2A
activity assay of pre-miR19b- and anti-miR19b–transduced cells relative
to the control (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001
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PP2A and BIM are both important regulators of apop-
tosis [37, 38]. In agreement with these findings, knock-
ing down PPP2R5E or BCL2L11 with shRNAs resulted
in lower TNFα/ActD-induced apoptosis (Fig. 6b, right
panel, compare solid and hatched white columns, or
solid and dotted white columns, respectively). In con-
trast, spontaneous apoptosis was only affected in the
BCL2L11 knockdown (Fig. 6b, left panel, compare solid
and dotted white columns). TNFα/ActD-induced apop-
tosis was increased 1.2 to 1.3-fold relative to control, ir-
respective of whether cells were co-transduced with
anti-miR-19b and shc002 (Fig. 6b, right panel, compare
solid white and grey columns) or shPPP2R5E and anti-
miR-19b (Fig. 6b, right panel, compare hatched
columns). In contrast, apoptosis enhancement was abro-
gated in cells co-transduced with anti-miR-19b and
shBCL2L11 (Fig. 6b, left and right panel, dotted col-
umns). Thus, miR-19b controls apoptosis by targeting
BCL2L11, whereas PPP2R5E seems to be less important
(summarized in Fig. 6e).
Conversely, miR-19b-induced proliferation was mainly
due to targeting PPP2R5E (Fig. 6c, e). This is based on the
finding that reduced BrdU incorporation in anti-miR-19b/
shc002 co-transduced cells (Fig. 6c, solid white and grey
columns) was reversed in anti-miR-19b/shPPP2R5E–co-
transduced cells (Fig. 6c, hatched columns). In contrast,
knocking down shBCL2L11 had no effect on miR-19b-
regulated proliferation (Fig. 6c, dotted columns).
Enhanced proliferation and reduced apoptosis both
contribute to clonogenic growth. Consistent with the re-
sults shown in Fig. 4c, attenuation of miR-19b repressed
clonogenic growth (Fig. 6d, solid columns), but knocking
down PPP2R5E or BCL2L11 only partially reversed
clonogenic growth of miR-19b attenuated cells (Fig. 6d,
hatched or dotted columns). Thus, PPP2R5E and
BCL2L11 act together to control clonogenic growth elic-
ited by miR-19b through regulation of proliferation and
apoptosis, respectively.
Discussion
MiRNAs participate in signaling pathways as signal am-
plifiers or attenuators and regulate the activity of
a
b c
d
Fig. 4 miR-19b regulates EGFR-induced cellular processes. a Spontaneous
(solid columns) and TNFα/AktD-induced apoptosis (hatched columns) of
EGFR mutant NSCLC transduced with anti-miR19b construct (n = 3).
Apoptosis was analyzed by caspase3/7 cleavage assay 2 h post
induction with TNFα/AktD. b BrdU incorporation and (c) clonogenic
growth of pre-miR19b or anti-miR19b–transduced PC9 cells (n = 3).
Cells were examined and imaged 8 days post-seeding. *, p < 0.05; **,
p < 0.01; ***, p < 0.001, ****, p < 0.0001. d Clonogenic growth of anti-
miR-19b and control-transduced PC9 (upper panel) and HCC4011 cells
(bottom panel) at different concentrations of gefitinib. Cell numbers
were determined 8 days after incubation with gefitinib. IC50 values
were calculated from dose-response curves
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downstream effector pathways, and allow crosstalk
between these pathways (reviewed by [15]). We show by
microarrays and bioinformatics analysis that miRNAs
that are regulated by the PI3K branch of the EGFR sig-
naling pathway are also effectors of this pathway. In
agreement with this finding, miR-100 [39], miR-125b
[25, 40] and miR-9 [41], which are induced by the PI3K
branch of EGFR, are able to enhance NF-κB activity by
targeting TRAF-7, TNFAIP3 and FoxO1, respectively.
Likewise, miR-205 induces parallel signaling pathways by
enhancing the expression of ERBB3 [42]. The oncomiR-
1 cluster, which includes miR-18a, miR-19a, miR-19b,
miR-20a and miR-20b, is another prominent example of
miRNAs involved in oncogenic processes in different
cancer systems. Conversely, miR-181a, which is nega-
tively correlated with PI3K activity, interferes with such
processes by targeting oncogenic KRAS [43] and Bcl2
[44]. Thus, PI3K-regulated miRNAs act as downstream
effectors of EGFR signaling. Interestingly, pathway ana-
lysis of the phosphoproteome dataset of miR-19b-
attenuated cells and pathway analysis of the gene target
dataset of the top 17 miRNAs that are dysregulated by
the PI3K inhibitor revealed very similar biological func-
tion diagrams (Additional file 5: Figure S4c). This may
suggest that the phenotype elicited by the combination
of all PI3K-regulated miRNAs may be recapitulated by
the phenotype elicited by miR-19b alone. In conclusion,
our results are consistent with a model that PI3K-
regulated miRNAs act in a concerted manner to modu-
late the activity of the EGFR signaling pathway.
Our results indicate that miR-19b and EGFR act to-
gether to control proliferation, migration and apoptosis
of EGFR mutant NSCLC in a synergistic manner, form-
ing part of the same signaling pathway. This was
confirmed by Western blot analysis showing enhanced
phosphorylation of the effectors of EGFR including ERK,
STAT and AKT by miR-19b overexpression. Thus,
although miR-19b is induced by the PI3K/AKT
branch, it activates all three major branches of EGFR
indicating that one role of miR-19b is to link these
signaling pathways.
How is this achieved? Phosphoproteomic analysis of
miR-19b-attenuated cells pinpoints PP2A as a common
regulator of ERK, STAT and AKT signaling by miR-19b.
PPP2R5E regulation by miR-19b was confirmed by lucif-
erase reporter assays, RT-qPCR, Western blot analysis
and PP2A phosphatase activity assays. Thus, PPP2R5E
Fig. 5 EGFR and miR-19b act together to control cell migration.
Wound closure assay of (a) PC9 and (b) HCC4011 cells. Wound closure
was monitored over a period of 24 h in the presence or absence of
0.625 μM gefitinib using the imaging system Cell-IQ. Gefitinib was added
immediately after injury of the monolayer. Results are presented as
mean ± SD (n = 6)
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serves as a hub for miR-19b-mediated crosstalk between
these pathways.
PPP2R5E is implicated in enhanced proliferation elic-
ited by miR-19b evident from the observation that en-
hanced proliferation of NSCLC cells elicited by miR-19b
was completely restored in the PPP2R5E knockdown. In
contrast, targeting PPP2R5E proved to be dispensable
for apoptosis resistance induced by miR-19b. Consistent
with these findings, PPP2R5E inhibits proliferation by
dephosphorylation of ERK rather than apoptosis [9, 45].
Interestingly, the proapoptotic BH3-only protein BIM
(encoded by BCL2L11), which is a master regulator of
cell death in cancer cells [38], is a relevant target of
miR-19b in spontaneous and TNFα/ActD-induced apop-
tosis. Enhanced apoptosis in miR-19b-attenuated cells is
restored in the BCL2L11 knockdown. In contrast, clono-
genic growth is only partially restored by targeting either
PPP2R5E or BCL2L11. One explanation for this finding
may be that clonogenic growth is affected by both prolif-
eration and apoptosis, and that only one of both
processes is restored in a single PPP2R5E or BCL2L11
knockdown. PTEN, a well-established target of miR-19b
[46], may potentially corroborate with PPP2R5E and
BCL2L11 in miR-19b-induced processes. It remains to
be shown if enhanced migration elicited by miR-19b is
due to targeting PTEN [21], PPP2R5E (our study) or a
combination of both.
Enforced expression of miR-19b triggers epithelial-
mesenchymal transition (EMT) [21]. However, in
contrast to our findings and findings obtained by others
[20], Li et al. reported that miR-19b overexpression was
also responsible for reduced proliferation of the NSCLC
cell line A549 [21]. This could be due to off-target
effects upon high level expression of miR-19b or cell-
type-specific effects. Alternatively, EMT and reduced
proliferation may appear during a later period following
a
c d e
b
Fig. 6 Distinct roles of PPP2R5E and BCL2L11 in PP2A activity, proliferation and apoptosis of miR-19b-attenuated PC9 cells. a PP2A activity, (b)
spontaneous (left panel) and TNFα/ActD-induced (right panel) apoptosis, (c) proliferation and (d) clonogenic growth of PC9 cells transduced with
anti-miR-19b (grey columns) or anti-miR control (αscr, white columns) in combination with shcontrol (sh002, solid), shPPP2R5E (hatched) and shBCL2L11
(dotted) (n = 3). Analysis was performed as described in the legend to Fig. 4. e Model showing EGFR/AKT-induced miR-19b, its targets and cellular
processes in which it is involved. ns, not significant. *, p < 0.05; **, p < 0.01; ***, p < 0.001, ****, p < 0.0001
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miR-19b induction. We found that miR-19b overex-
pressing cells lost their proliferation phenotype upon
long term culture, but this was not associated with the
appearance of EMT markers (data not shown).
Novel forms of therapies aiming at reactivating PP2A
may become important for the treatment of lung cancer
in the future. Activators of PP2A such as SMAPs
(reviewed by [47]) or inhibitors of negative regulators
such as bortezomib or erlotinib, that restore PP2A activ-
ity by targeting CIP2A [48], are currently tested in clin-
ical phase I/II studies. These drugs could possibly be
exploited for the therapy of EGFR or KRAS-driven
NSCLC. One potential drawback may be that all PP2A
holoenzymes are equally affected using these pharmaco-
logical approaches which may also have an impact on
normal tissue. We found that PPP2R5E contributed to
30% PP2A activity in PC9 cells, but PP2A activity was
significantly enhanced in miR-19b-attenuated cells which
was associated with reduced clonogenic growth. In
addition, we found that attenuation of miR-19b sensi-
tized cells to gefitinib treatment. Thus, administering
antagomiRs to block enhanced levels of miR-19b may be
an interesting alternative therapeutic option as it specif-
ically restores PPP2R5E expression in the tumour tissue.
Conclusion
We report that miR-19b acts with other PI3K-regulated
miRNAs in a concerted manner as signal amplifiers to
modulate the activity of the EGFR pathway. Serine/
threonine phosphatase PP2A as well as BCL2L11 were
defined as targets of miR-19b which serve as hubs allow-
ing cross-talk between signaling pathways. A deeper un-
derstanding of underlying molecular processes of EGFR
signaling involving miRNAs may provide insights into
improving the management of EGFR-mutant lung cancer
patients treated with TKIs. In addition, this work may
have therapeutic implications since targeting miR-19b
may be a means of affecting PP2A expression and
thereby modulating the activity of EGFR signaling.
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Additional file 2: Figure S1. Pathway analysis of PI3K-regulated microRNAs.
a Top 24 regulated pathways sorted by their significance. The greyscale
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predicted as a target, divided by the total number of pathway elements.
The –log10 p-value cut off was set to 1.3. b Word cloud representing
pathway elements (mRNA). The font size of a pathway element is
characterized by its frequency of occurrence in the pathway analysis
data set. The colors are not corresponding to any feature. Pathways
elements are ordered alphabetically from left to right. c Representation
of biological functions corresponding to pathways built based on
miRNA targets. Number of pathways participating in each biological
function is indicated on the axis of the radar graph. (PDF 4333 kb)
Additional file 3: Figure S2. Cell viability of NSCLC cells in the
presence of different TKIs. Cell viability was assessed using metabolic
resazurin assay (Sigma-Aldrich). In brief cells were seeded at a density of
1500 cells/well in 96-well plate. Treatment was started 24 h post seeding,
with inhibitors at the given concentrations shown in the figure over a
time period of 72 h. Cell viability was assayed 3 h after adding resazurin
using an infinite 200 reader (Tecan, Maennedorf, Switzerland). Results are
presented as mean relative viability relative to DMSO treated cells ±SD,
(n = 3). (PDF 594 kb)
Additional file 4: Figure S3. miR-19b expression levels of pre-miR-19b
and antimiR-19b-transduced NSCLC cells. miR-19b expression levels were
analyzed by real-time qPCR relative to RNU48. Results are presented as
mean ± SD (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001. (PDF 151 kb)
Additional file 5: Figure S4. Pathway analysis based on the dataset
from the phosphatase array of miR-19b attenuated PC9 cells. a Top 25
regulated pathways sorted by their significance. Color intensity represents
the degree of regulation. Orange color represents activation and blue
color represents inhibition of a pathway, white columns indicates minimum
regulatory direction. b Relationship between the main upstream regulator
EGF and the downstream effectors based on phospho-array data. Elements
that are inhibited by de-phosphorylation are indicated in green and
elements that are activated by de-phosphorylation are indicated in orange.
c Comparison of regulated biological functions based on phosphatase array
dataset (red) with microRNA expression dataset (green). Number of
pathways involved in each biological function is indicated on the axis of the
radar graph. The overlap of the two graphs is shown in brown. d Gene
network analysis of upregulated phosphatases (orange symbols), which
serve as hubs for responsive elements such as kinases (green symbols).
Inhibitory interactions are indicated by blue lines and activating interactions
are indicated by orange lines p < 0.05. (PDF 2995 kb)
Additional file 6: Figure S5. miR-19b confers apoptosis resistance in
EGFR mutant NSCLC cells. a Representative examples of dot plots and
densitometric plots of PC9 cells transduced with GFP/anti-miR-19b
(αmiR19b) or GFP/anti-miR scramble control (αscr) in the presence
(TNFα+ActD) or absence (cRPMI) of an apoptotic trigger. GFP-positive
cells were analysed for Annexin V / propidium iodide (Annexin V / PI) by
flow cytometry. b Percent Annexin V-positive, PI-positive and AnnexinV/
PI-negative cells of three EGFR mutant NSCLC cell lines in the presence
or absence of an apoptotic trigger (n = 3). (PDF 621 kb)
Additional file 7: Figure S6. Clonogenic growth in the presence of
gefitinib. Images of 6-well plates 8 days post seeding captured from the
clonogenic growth assay described in Fig. 4D. Experiments performed
with PC9 cells are shown in the upper part and experiments performed
with HCC4011 cells are shown in the bottom of the figure. Gefitinib
concentrations are indicated below the images. (PDF 5244 kb)
Additional file 8: Video S1. Migration is reduced in miR-19b attenuated
cells. Wound healing was analysed by kinetic live cell imaging using a
cell-IQ instrument. Video 1A showing anti-miR-transduced. PC9 cells
(green) and control (red) and video 1B showing anti-miR scramble
control transduced PC9 cells (green) and control (red) are appended to
the supplemental material. (ZIP 6645 kb)
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